ArticleJournal of bioenergetics and biomembranes2026
APPL1 attenuates DHEA-induced oxidative injury in granulosa cells by enhancing mitophagy and suppressing ferroptosis: implications for polycystic ovary syndrome.
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder frequently associated with granulosa cell dysfunction. However, its underlying molecular mechanisms remain unclear. Therefore, we aimed to examine the role of APPL1 in PCOS and determine whether it attenuates oxidative stress and ferroptosis by modulating mitophagy in granulosa cells. An in vitro PCOS model was established by treating KGN cells with dehydroepiandrosterone (DHEA), with or without concurrent APPL1 overexpression. An in vivo PCOS rat model was established by DHEA injection, followed by intraovarian lentiviral delivery to overexpress APPL1. Oxidative stress, ferroptosis, and mitophagy markers were also evaluated. Mdivi-1, the DRP1/mitochondrial fission inhibitor, was used to examine this pathway. APPL1 expression was significantly reduced in DHEA-treated KGN cells and PCOS rat ovaries. APPL1 overexpression markedly attenuated DHEA-induced oxidative stress and ferroptosis in vitro, as evidenced by reduced ROS, MDA, 8‑OHdG, Fe²⁺, and ACSL4 levels, together with restored antioxidant enzyme activities and GPX4/SLC7A11 expression. Concurrently, APPL1 overexpression enhanced mitophagy, as shown by an increased LC3-II/LC3-I ratio and decreased p62 and TOMM20/COX IV levels. Treatment with Mdivi-1 attenuated these protective effects. APPL1 overexpression improved estrous cyclicity, attenuated hyperandrogenism, ameliorated ovarian morphology, and alleviated ovarian oxidative stress and ferroptosis in PCOS rats. APPL1 protected granulosa cells against DHEA-induced oxidative injury and ferroptosis by enhancing mitophagy in preclinical PCOS models. These findings provide mechanistic insights into PCOS pathogenesis and identify the APPL1-mitophagy axis as a potential target for PCOS intervention.
Indexed as
Identifiers
42867751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.